Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes
necessary for tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients
who have unresectable and/or metastatic salivary gland cancer.